1355162-34-3

Basic information

• Product Name: 5-([(2-chloroquinolin-3-yl)methyl]sulfanyl)-N-[(4-fluorophenyl)methylidene]-1,3,4-thiadiazol-2-amine
• Synonyms: 5-([(2-chloroquinolin-3-yl)methyl]sulfanyl)-N-[(4-fluorophenyl)methylidene]-1,3,4-thiadiazol-2-amine
• CAS NO: 1355162-34-3
• Molecular Weight: 414.914
• Mol File: 1355162-34-3.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 5-([(2-chloroquinolin-3-yl)methyl]sulfanyl)-N-[(4-fluorophenyl)methylidene]-1,3,4-thiadiazol-2-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-([(2-chloroquinolin-3-yl)methyl]sulfanyl)-N-[(4-fluorophenyl)methylidene]-1,3,4-thiadiazol-2-amine(1355162-34-3)
• EPA Substance Registry System: 5-([(2-chloroquinolin-3-yl)methyl]sulfanyl)-N-[(4-fluorophenyl)methylidene]-1,3,4-thiadiazol-2-amine(1355162-34-3)

Safety Data

• Hazardous Substances Data: 1355162-34-3(Hazardous Substances Data)

Upstream product

• 90097-52-2 2-chloro-3-(chloropmethyl)quinoline 
• 125917-60-4 2-chloro-3-(hydroxymethyl)quinoline 
• 73568-25-9 2-chloro-3-quinoline carboxaldehyde 
• 1003810-64-7 5-([(2-chloroquinolin-3-yl)methyl]sulfanyl)-1,3,4-thiadiazol-2-amine 
• 459-57-4 4-fluorobenzaldehyde 

Downstream Products

• 1297453-67-8 5-([(2-chloroquinolin-3-yl)methyl]sulfanyl)-N-(4-fluorobenzyl)-1,3,4-thiadiazol-2-amine 

Relevant articles and documents

Design, synthesis and screening of quinoline-incorporated thiadiazole as a potential anticonvulsant

A series of quinoline-incorporated substituted thiadiazole were designed and synthesized using appropriate synthetic route keeping in view the structural requirement of pharmacophore and evaluated for anticonvulsant and CNS activities. After intraperitoneal injection to mice, some synthesized derivatives were examined in the maximal electroshock seizure (MES) and subcutaneous pentylenetetrazol (scPTZ)-induced seizure and neurotoxicity screens. Those found potent were also evaluated for behavioural impairment and depression activity. Among the compounds tested, 6d and 6e showed protection from seizures in both the animal models at dose level of 30mg/kg while 7f showed protection against both models at 100mg/kg dose level. These compounds exhibited lesser CNS depression and neurotoxicity compared with clinically effective drug. A series of quinoline incorporated substituted thiadiazole were designed & synthesized using appropriate synthetic route keeping in view the structural requirement of pharmacophore and evaluated for anticonvulsant and CNS activities. Among screened compounds 6d & 6e showed protection from seizures in both MES and scPTZ models at dose level (30 mg/kg).